Your browser doesn't support javascript.
loading
Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer.
Ivanova, Elena; Kuraguchi, Mari; Xu, Man; Portell, Andrew J; Taus, Luke; Diala, Irmina; Lalani, Alshad S; Choi, Jihyun; Chambers, Emily S; Li, Shuai; Liu, Shengwu; Chen, Ting; Barbie, Thanh U; Oxnard, Geoffrey R; Haworth, Jacob J; Wong, Kwok-Kin; Dahlberg, Suzanne E; Aref, Amir A; Barbie, David A; Bahcall, Magda; Paweletz, Cloud P; Jänne, Pasi A.
Afiliación
  • Ivanova E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kuraguchi M; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Xu M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Portell AJ; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Taus L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Diala I; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Lalani AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Choi J; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Chambers ES; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Li S; Puma Biotechnology Inc., Los Angeles, California.
  • Liu S; Puma Biotechnology Inc., Los Angeles, California.
  • Chen T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Barbie TU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Oxnard GR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Haworth JJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wong KK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Dahlberg SE; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
  • Aref AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Barbie DA; Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Bahcall M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Paweletz CP; Department of Medicine, Division of Hematology and Medical Oncology, New York University Langone Medical Center, New York, New York.
  • Jänne PA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Clin Cancer Res ; 26(10): 2393-2403, 2020 05 15.
Article en En | MEDLINE | ID: mdl-32034078
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Receptor ErbB-2 / Neoplasias Pulmonares / Mutación Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Receptor ErbB-2 / Neoplasias Pulmonares / Mutación Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article